This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kim, D. Articles by Yan, C. Search for Related Content PubMed PubMed Citation Articles by Kim, D. Articles by Yan, C. Related Collections Gene expression Endothelium/vascular type/nitric oxide

(Circulation. 2001;104:2338.)
© 2001 American Heart Association, Inc.

Basic Science Reports

Upregulation of Phosphodiesterase 1A1 Expression Is Associated With the Development of Nitrate Tolerance

Dongsoo Kim, MD; Sergei D. Rybalkin, PhD; Xinchun Pi, MS; Yining Wang, MD; Changxi Zhang, MD; Thomas Munzel, MD; Joseph A. Beavo, PhD; Bradford C. Berk, MD PhD; Chen Yan, PhD

From the Department of Medicine (D.K., X.P., C.Z., B.C.B., C.Y.) and Department of Surgery (Y.W.), University of Rochester, Rochester, NY; the Department of Pharmacology, University of Washington, Seattle (S.D.R., J.A.B.); and the Division of Cardiology, University of Eppendorf, Hamburg, Germany (T.M.).

Correspondence to Chen Yan, PhD, Center for Cardiovascular Research, University of Rochester, 601 Elmwood Ave, Box 679, Rochester, NY 14642-8679. E-mail chen_yan{at}urmc.rochester.edu

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Background— The efficacy of nitroglycerin (NTG) as a vasodilator is limited by tolerance, which develops shortly after treatment begins. In vascular smooth muscle cells (VSMCs), NTG is denitrated to form nitric oxide (NO), which activates guanylyl cyclase and generates cGMP. cGMP plays a key role in nitrate-induced vasodilation by reducing intracellular Ca²⁺ concentration. Therefore, one possible mechanism for development of nitrate tolerance would be increased activity of the cGMP phosphodiesterase (PDE), which decreases cGMP levels.

Methods and Results— To test this hypothesis, rats were made tolerant by continuous infusion of NTG for 3 days (10 µg · kg^-1 · min^-1 SC) with an osmotic pump. Analysis of PDE activities showed an increased function of Ca²⁺/calmodulin (CaM)–stimulated PDE (PDE1A1), which preferentially hydrolyzes cGMP after NTG treatment. Western blot analysis for the Ca²⁺/CaM-stimulated PDE revealed that PDE1A1 was increased 2.3-fold in NTG-tolerant rat aortas. Increased PDE1A1 was due to mRNA upregulation as measured by relative quantitative reverse transcription–polymerase chain reaction. The PDE1-specific inhibitor vinpocetine partially restored the sensitivity of the tolerant vasculature to subsequent NTG exposure. In cultured rat aortic VSMCs, angiotensin II (Ang II) increased PDE1A1 activity, and vinpocetine blocked the effect of Ang II on decrease in cGMP accumulation.

Conclusions— Induction of PDE1A1 in nitrate-tolerant vessels may be one mechanism by which NO/cGMP-mediated vasodilation is desensitized and Ca²⁺-mediated vasoconstriction is supersensitized. Inhibiting PDE1A1 expression and/or activity could be a novel therapeutic approach to limit nitrate tolerance.

Key Words: nitrates • phosphodiesterase • vasculature

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
Nitroglycerin (NTG) remains one of the foremost drugs in the treatment of angina pectoris. When given in the short term, NTG has potent vasodilator capacities on arteries, veins, and coronary collateral vessels.¹ NTG induces vasorelaxation by releasing NO. NO activates soluble guanylyl cyclase and subsequently increases cGMP. cGMP in turn activates a cGMP-dependent protein kinase that has been shown to mediate vasorelaxation via phosphorylation of proteins that regulate intracellular Ca²⁺ levels.² The efficacy of chronic NTG administration, however, is limited by the rapid development of tolerance,³ involving decreased vascular sensitivity and diminished cGMP elevations in vascular smooth muscle cells (VSMCs) in response to continued nitrate treatment. Nitrate tolerance is also associated with cross-tolerance to other endothelium-dependent and -independent vasodilators.² Several mechanisms have been proposed to account for this phenomenon, such as neurohumoral counterregulation⁴ or mechanisms intrinsic to the vascular tissue itself, such as desensitizing NO/cGMP signaling and responses.² Chronic NTG treatment has also been shown to be associated with an increase in sensitivity to vasoconstrictors such as catecholamines, angiotensin (Ang) II, KCl, and serotonin,⁵ all of which may compromise the vasodilating capacity of NTG, thereby contributing to tolerance. Another aspect of organic nitrate therapy is the development of rebound ischemia due to coronary rebound constriction after abrupt cessation of long-term NTG therapy.⁶

See p 2263

cGMP appears to be a key player in NTG-mediated vasorelaxation, and the cGMP level is highly regulated by phosphodiesterase (PDE). At least 4 different major PDE activities have been identified in VSMCs (Table). Different PDEs play distinct roles in controlling vascular tone.⁷ In this study, we found that the activity and expression of Ca²⁺/calmodulin (CaM)–stimulated PDE (PDE1A1), which preferentially hydrolyzes cGMP, were induced by NTG treatment. Vinpocetine, a selective inhibitor of the PDE1 family, was able to partially restore the sensitivity of tolerant vessels to subsequent NTG exposure. These findings indicate that increased PDE1A1 activity can decrease cGMP levels, which may contribute at least in part to the attenuation of the NTG-mediated vasodilation as well as the supersensitivity to vasoconstrictors.

View this table: [in this window] [in a new window]   Table 1. Major PDE Isoforms Present in Rat VSMCs

	Methods

Top Abstract Introduction Methods Results Discussion References

 
Development of Nitrate Tolerance In Vivo
Nitrate tolerance was induced as described previously.⁸ Male Sprague-Dawley rats (Charles River Laboratories, Wilmington, Mass; 250 to 300 g) were anesthetized with ketamine 40 mg/kg, xylazine 0.5 mg/kg, and acepromazine 5 mg/kg IP. An osmotic minipump (model 2 ML1, Alza Corp) filled with either NTG (Zeneca Inc) or vehicle (propylene glycol) was implanted subcutaneously at the dorsum of the neck. NTG was infused at a rate of 10 µg · kg^-1 · min^-1 for 3 days.

To assess tolerance, mean arterial pressure (MAP) was continuously monitored by a catheter in the right common carotid artery on a polygraph recorder (Grass Instruments). Bolus doses of NTG or hydralazine were administered through the right jugular vein.

Anion-Exchange Chromatography
Three thoracic aortas were pooled and homogenized. The supernatant of the tissue extract was fractionated as described previously.⁹ Fractions containing PDEs were assayed for PDE activity or subjected to Western blot analysis.

In Vitro PDE Enzyme Assay
PDE assays were carried out according to established procedures.⁹

Western Blot Analysis
Western blots for PDE1A1 and PDE5A1 with isoform-specific antibodies were carried out as described previously.^9,10

Relative Quantitative RT-PCR and Northern Blot Analysis
Tissue RNA was extracted with a Total RNA Isolation Kit (Ambion). First-strand cDNA was synthesized with the SuperScript Preamplification System (Gibco-BRL). Relative quantitative reverse transcription–polymerase chain reaction (RT-PCR) was performed with 18s rRNA as an internal control by use of Ambion’s competimer technology. Isoform-specific primers were used to generate the 281-bp PCR product for PDE1A1 or 335-bp PCR product for PDE5A1. PCR products were separated on a 2% agarose gel, stained with ethidium bromide, and visualized under UV light. The relative intensity of PDE1A1 or PDE5A1 PCR products was determined by densitometry. Northern blot analysis was performed with the Clontech hybridization system according to the manufacturer’s protocol. The PCR product specific to PDE1A1 or PDE5A1, mentioned above, was used as a probe.

Contraction Study
Ex vivo evaluation of nitrate tolerance and reversal was performed as described previously.¹¹ Aortic rings were stretched with a preload of 2 g, equilibrated, and then preconstricted with phenylephrine. Preconstricted aortic rings were pretreated with vehicle or 100 µmol/L vinpocetine for 10 minutes, followed by exposure to ascending concentrations of NTG.

cGMP Assays
Aortic extracts were prepared by homogenization in cold 5% trichloroacetic acid. VSMC extracts were prepared by lysis of cells in cold 100% ethanol. A cGMP ¹²⁵I radioimmunoassay kit (NEN) was used for measurement of cGMP levels as described in the manufacturer’s protocol. Protein levels were determined by the method of Bradford (Bio-Rad).

VSMC Culture
Rat aortic VSMCs were isolated and maintained as described previously.¹² VSMCs (passages 6 to 9) were growth-arrested for 48 hours before the indicated drug treatment.

Measurement of Ca²⁺/CaM-Stimulated PDE Activity
The technique involves extraction and assay of enzyme activity at a low temperature and in the presence of trifluoperazine to prevent the dissociation and reassociation of the ternary Ca²⁺-CaM-PDE complex during cell disruption.¹³ The percent maximal CaM-stimulated PDE activity was computed as (activity without CaM or EGTA-activity with EGTA)/(activity with CaM-activity with EGTA)x100.

Statistical Analysis
One- or 2-way ANOVA was used to compare differences between treatment means (expressed as mean±SEM). After ANOVA, comparison of 2 populations was made by Student’s unpaired t test. A value of P<0.05 was considered significant.

	Results

Top Abstract Introduction Methods Results Discussion References

 
Induction of In Vivo Nitrate Tolerance
To assess the development of nitrate tolerance in vivo, the hypotensive and vasorelaxant effects of NTG were examined. There was no significant difference in baseline MAP between the vehicle- and NTG-treated groups (104.3±3.9 versus 100.8±4.1 mm Hg). In the vehicle-treated group, acute NTG challenges caused a dose-dependent drop in MAP (Figure 1), but 3-day NTG treatment significantly decreased the NTG-induced drop in MAP (Figure 1), indicating that changes in MAP were significantly blunted in the NTG-treated groups. The hydralazine (1 mg/kg bolus)–induced drop in MAP was similar in both groups (Figure 1), indicating that NO-independent vasodilation was not different between the 2 groups.

View larger version (15K): [in this window] [in a new window]   Figure 1. Hypotensive effects of bolus doses of NTG in vehicle- or NTG-pretreated rats for 3 days. Hydralazine was used as NO-independent vasodilator. Values are mean±SEM of % changes from baseline. **P<0.01 vs baseline within each group (n=5 to 6).

Increased Ca²⁺/CaM-Stimulated PDE Activity in Nitrate-Tolerant Rat Aortas
To examine the change of PDE activity in nitrate-tolerant vessels, we performed PDE assays. cGMP hydrolytic activities in tolerant aortas were significantly higher than in control aortas (Figure 2A), whereas cAMP hydrolytic activities were similar (Figure 2B). In the presence of Ca²⁺/CaM, cGMP hydrolytic activities were increased much more in tolerant aortas than in control aortas (Figure 2A). This observation suggests that the activity of a Ca²⁺/CaM-stimulated PDE, which preferentially hydrolyzes cGMP, is induced by NTG treatment.

View larger version (36K): [in this window] [in a new window]   Figure 2. PDE activities in aortas from control or tolerant rats. PDE assays were performed in tissue extracts with either 1 µmol/L cGMP (A) or 1 µmol/L cAMP (B) in presence of either 1 mmol/L EGTA or 0.8 mmol/L CaCl2 and 4 µg/mL CaM. Values are mean±SEM (n=3). **P<0.01 vs control. Representative data showing PDE activities of anion-exchange high-performance liquid chromatography fractions of rat aortas pooled from 3 control (C) or tolerant (D) rats.

To confirm these results and further separate different PDE activities, we resolved the PDE activities of control and tolerant aortas by high-performance liquid chromatography. In fractions 18 to 30, which contain enzymes of both the PDE1 and PDE5 families,⁹ cGMP hydrolytic activity of tolerant aortas is significantly higher in the presence of Ca²⁺/CaM than in the presence of EGTA (Figure 2C). In contrast, fractions 18 to 30 from control vessels hydrolyzed cGMP to a similar extent in the presence of EGTA or Ca²⁺/CaM (Figure 2D). These data indicate that increased cGMP hydrolytic activity in tolerant vessels is mainly the Ca²⁺/CaM-stimulated PDE activity.

Protein Level of PDE1A1, but Not PDE5A1, Is Increased in Nitrate-Tolerant Aortas
To determine whether the induction of PDE activity in tolerant vessels was due to increases in the enzyme level, Western blot analyses with PDE1A- and PDE5A-specific antibodies were performed (Figure 3). The PDE1A1 protein level was increased 2.3-fold in tolerant vessels (Figure 3A), whereas the PDE5A1 protein level was not significantly changed (Figure 3B). These results indicate that PDE1A1, a Ca²⁺/CaM-stimulated PDE with much higher affinity for cGMP than for cAMP,¹⁴ is selectively upregulated in nitrate-tolerant vessels.

View larger version (35K): [in this window] [in a new window]   Figure 3. Western blot analysis showing increased protein level of PDE1A1 (A) but not PDE5A1 (B) in tolerant and control rat aortas. Fold increase vs control is indicated and shown as average from 2 independent experiments (total 6 aortas for each group).

mRNA Level of PDE1A1, but Not PDE5A1, Is Increased in Nitrate-Tolerant Aortas
To determine whether the increase in protein level of PDE1A1 was due to an increase in its mRNA level, relative quantitative RT-PCRs using PDE1A1- and PDE5A1-specific primers were performed (Figure 4). mRNA levels of PDE1A1 in tolerant aortas were increased by 2.4-fold compared with control aortas (Figure 4A). In contrast, the PDE5A1 mRNA level was not significantly altered (Figure 4B). We obtained similar results by Northern blot analysis (Figure 4C).

View larger version (43K): [in this window] [in a new window]   Figure 4. mRNA level of PDE1A1 but not PDE5A1 is increased in nitrate-tolerant rat aortas. Relative quantitative RT-PCR reactions of PDE1A1 (A) and PDE5A1 (B) in control and tolerant rat aortas. 18s rRNA was used as internal control. Summary data were normalized to control, which was arbitrarily set at 1.0 for each experiment. Values are mean±SEM (n=8). **P<0.01 vs control. C, Northern blot analysis.

Effects of PDE1 Family–Selective Inhibitor Vinpocetine on Reversal of Nitrate Tolerance Ex Vivo
NTG-treated aortic rings exhibited a significantly decreased vasorelaxation response to subsequent NTG compared with control. Preincubation of tolerant rings with vinpocetine, however, restored the vasorelaxant effect of NTG. Vinpocetine also potentiated the vasorelaxant effect of NTG in control rings (Figure 5A).

View larger version (24K): [in this window] [in a new window]   Figure 5. Effects of PDE1A1 inhibitor on reversal of nitrate tolerance ex vivo. A, Effects of vinpocetine on vasorelaxation response to NTG in control and tolerant rat aortic rings. Data were calculated as relative % relaxation. B, Effects of vinpocetine on NTG-evoked cGMP levels in control and tolerant rat aortic rings. Aortic rings were pretreated with vehicle or 100 µmol/L vinpocetine for 30 minutes and exposed to 300 nmol/L NTG or vehicle for 30 seconds. Values are mean±SEM (n=3 to 4). *P<0.05, **P<0.01 vs control. aP<0.01 vs vehicle-treated group. bP<0.01 vs NTG-treated group in absence of vinpocetine.

We also tested the effects of vinpocetine on nitrate tolerance–associated attenuation of cGMP elevations in response to subsequent NTG exposure as shown in Figure 5B. The basal cGMP concentrations were not significantly different between tolerant and control aortic rings. After exposure to NTG, an NTG-induced increase in cGMP in tolerant rings was clearly decreased compared with control, and vinpocetine enhanced the NTG-induced increase in cGMP in tolerant rings, suggesting that PDE1A1 inhibitor is able to partially reverse the nitrate tolerance of cGMP response.

Stimulation of PDE1A1 Activity by Ang II and the Role of PDE1A1 in Ang II–Mediated Inhibition of Atrial Natriuretic Peptide–Evoked cGMP Accumulation in VSMCs
To study the mechanism by which induction of PDE1A1 might cause nitrate tolerance and nitrate tolerance–induced supersensitivity to vasoconstrictors, we measured the effects of Ang II on PDE1A1 activity, which represent the extent of activation in vivo. As shown in Figure 6A, PDE1A1 activity in control VSMCs is 47.8% of the maximum. Ang II increased PDE1A1 activity to 95.6% of the maximum. This observation is consistent with the time course of force production and changes in intracellular Ca²⁺ concentration in response to Ang II treatment¹⁵ and suggests that Ang II is able to stimulate the PDE1A1 activity, probably via an Ang II– mediated increase in Ca²⁺ concentration.

View larger version (20K): [in this window] [in a new window]   Figure 6. Effect of Ang II on activation PDE1A1 in VSMCs and role of PDE1A1 in Ang II–mediated inhibition of ANP-induced cGMP accumulation. A, Effects of Ang II on PDE1A1 activity representing extent of activation in vivo. Growth-arrested VSMCs were treated with or without 400 nmol/L Ang II for indicated time. Values are mean±SEM (n=3). **P<0.01 vs control, *P<0.05 vs control. B, Effects of vinpocetine on Ang II–mediated inhibition of ANP-induced cGMP accumulation. Growth-arrested VSMCs were pretreated with or without 100 µmol/L vinpocetine for 30 minutes and then treated with or without 100 nmol/L ANP, 400 nmol/L Ang II, or both simultaneously for 1 minute. Values are mean±SEM (n=4 to 7). **P<0.01 vs ANP alone.

To further determine the functional effects of PDE1A1 activity stimulated by Ang II, we measured the effect of Ang II on cGMP accumulation in response to atrial natriuretic peptide (ANP). The addition of ANP to VSMCs rapidly increased intracellular cGMP. Simultaneous addition of Ang II markedly decreased the ANP-induced cGMP accumulation. Vinpocetine significantly blocked the inhibitory effect of Ang II (Figure 6B). These results suggest that PDE1A1 in VSMCs plays a major role in mediating inhibition of ANP-evoked cGMP accumulation by Ang II.

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
The present study showed, first, that in vivo NTG treatment to induce hemodynamic nitrate tolerance increased PDE1A1 enzyme activity, protein levels, and mRNA expression; second, that inhibition of PDE1A1 in tolerant vessels restored vasorelaxation and cGMP response to subsequent NTG exposure; and third, that PDE1A1 plays an important role in regulation of intracellular cGMP levels in response to vasodilators and vasoconstrictors. The upregulation of PDE1A1 may therefore provide a new mechanism to explain, at least in part, the decreased sensitivity of the vasculature to NTG and the phenomenon of enhanced vasoconstriction observed after chronic NTG treatment (Figure 7).

View larger version (26K): [in this window] [in a new window]   Figure 7. Schematic showing role of PDE1A1 in nitrate tolerance. Endothelium-dependent and -independent nitrovasodilators such as acetylcholine (Ach), NTG, and ANP activate soluble guanylyl cyclase (GC), stimulating cGMP formation. cGMP leads to vasodilation by decreasing intracellular Ca2+. Vasoconstrictors such as Ang II, norepinephrine (NE), and endothelin (ET)-1 cause increase in intracellular Ca2+, leading to vasoconstriction. cGMP is a key player in regulating vascular tone by controlling Ca2+ levels, which regulates vascular contractility. An increase in PDE1A1 activity by chronic NTG treatment leads to reduced cGMP accumulation in response to further stimulation with vasodilators, thereby causing a decreased sensitivity of vasculature to NTG. Induction of PDE1A1 also increases magnitude of vasoconstrictor-mediated attenuation of cGMP accumulation, which may contribute to phenomenon of supersensitivity to vasoconstrictors in NTG-treated vessels.

Role of PDE1A1 in Nitrate Tolerance
PDE1A1 was previously shown to be important for the regulation of vascular cGMP levels and reactivity.^7,16 The findings of the present study concur with this concept. We found that NTG treatment significantly increases PDE1A1 activity and expression. An increase in PDE1A1 activity will reduce cGMP accumulation, thereby causing the decreased sensitivity of the vasculature to subsequent NTG treatment, because cGMP is a key player in regulation of vascular relaxation by decreasing intracellular Ca²⁺ concentration via activation of downstream cGMP-dependent protein kinase-I.

Changes in PDE1A1 expression in intact aortas after NTG treatment most likely occurs in VSMCs, because PDE1A1 immunoreactivity was restricted to the VSMC layer in vessels, as shown by immunocytochemical analysis.¹⁰ Endothelium has been believed to be important in the genesis of tolerance, because removal of endothelium reduces nitrate tolerance significantly, although not completely.¹⁷ The fact that PDE1A1 is stimulated by vasoactive reagents released from endothelium, such as endothelin-1 and local Ang II, suggests that the effect of PDE1A1 is much greater in the presence of endothelium than in the absence of endothelium, which is consistent with the observation that nitrate tolerance is much more severe with endothelium than without and demonstrates the importance of PDE1A1 in tolerance. In addition, many previously published studies in which NTG was administered in vivo have demonstrated cross-tolerance to endothelium-dependent vasodilators and other nitrovasodilators.^17–19 Induction of PDE1A1 activity also fits the presence of cross-tolerance in the setting of NTG tolerance.

An induction of PDE1A1 would also explain, at least in part, the phenomenon of supersensitivity to vasoconstrictors in NTG-tolerant vessels observed in experimental animals and human studies.^5,18 Most vasoconstrictors, such as norepinephrine, Ang II, and endothelin-1, increase the intracellular Ca²⁺. PDE1A1 activity can be stimulated by Ca²⁺ >10-fold in vitro.¹⁴ Our observations that Ang II stimulated PDE1A1 activity and PDE1A1 inhibitor blocked Ang II–mediated attenuation of ANP-evoked cGMP accumulation support the role of PDE1A1 in vasoconstrictor-mediated regulation of vascular cGMP levels. Such an attenuation of ANP- or NTG-evoked cGMP accumulation has also been observed with many other Ca²⁺-raising vasoconstrictors.^18,20 These observations together suggest that the vasoconstriction effects of these vasoconstrictors are at least partially mediated by blockade of the vasodilatory pathway of cGMP and support the idea that induction of PDE1A1 increases the magnitude of vasoconstrictor-mediated attenuation of cGMP accumulation, which may explain the phenomenon of supersensitivity to vasoconstrictors in NTG-tolerant vessels.

Rebound angina, associated with an intermittent-treatment regimen for the prevention of nitrate tolerance, can be a serious problem and may result in death.²¹ This rebound effect is believed to be associated with increased sensitivity to vasoconstrictors.⁶ Thus, supersensitivity to vasoconstrictors mediated by induction of PDE1A1 and the subsequent reduced vasodilatory forces on removal of nitrates together may explain the rebound phenomenon. Inhibition of PDE1A1 may be a novel therapeutic tool for the prevention of the rebound phenomenon.

Mechanisms Underlying Nitrate Tolerance
Nitrate tolerance seems to be multifactorial. Several mechanisms have been proposed to explain the phenomenon of nitrate tolerance. As a vasodilator, NTG lowers blood pressure, which in turn activates neurohumoral counterregulatory mechanisms, such as an activation of the renin-angiotensin system, increases in vasopressin levels, intravascular volume expansion, and increases in catecholamine release. These circulating vasoconstrictor forces may limit NTG-mediated vasodilation (pseudotolerance). Induction of PDE1A1 would enhance the vasoconstrictor forces.

Studies with isolated vessels from NTG-treated animals also show decreased sensitivity to NTG in the absence of the neurohumoral environment, pointing to intrinsic abnormalities of the tolerant vasculature itself. In particular, multiple steps in NO/cGMP signaling have been found to be affected. These include impaired nitrate biotransformation²²; overproduction of reactive oxygen species, which reduces NO bioavailability¹⁷; decrease and increase of cGMP metabolic enzymes, such as guanylyl cyclase and PDE, respectively^19,23; and attenuation of the downstream cGMP-dependent protein kinase activity.²⁴ Our observation that inhibition of PDE1A1 partially restores the cGMP elevation and vasorelaxation to subsequent NTG exposure in tolerant vessels is consistent with the proposal that nitrate tolerance is contributed to by multiple factors.

Effects of PDE Inhibition on Tolerance
PDE1 isoforms are structurally closer to PDE5 isoforms than any other cAMP-hydrolyzing PDE isoforms in VSMCs. Zaprinast, which inhibits both PDE1 and PDE5 isoforms with higher sensitivity to PDE5, has been shown to be able to reverse NTG tolerance in vitro and in vivo.^11,25 The effect of zaprinast on the reversal of nitrate tolerance may be due to the inhibition of both PDE1A1 and PDE5A1. Inhibition of PDE5A1 activity is able to diminish nitrate tolerance because of augmentation of the response to organic nitrates, even though PDE5A1 expression is not altered in the setting of nitrate tolerance.

Vinpocetine is the most selective inhibitor identified to date for PDE1 isozymes. Using recombinant PDE1A1 and PDE5A1 expressed in COS-7 cells, we found that vinpocetine at 100 µmol/L inhibited PDE1A1 activity up to 90% but PDE5A1 activity <5% (data not shown). This is consistent with the previous observation that the IC₅₀ for vinpocetine to inhibit the partially purified PDE5A1 was >1 mmol/L.¹⁶ Thus, vinpocetine at a concentration of 100 µmol/L appears to be specific to PDE1A1 in VSMCs. In this study, we have demonstrated the ability of vinpocetine to limit nitrate tolerance in both restoration of vasorelaxation and cGMP response to NTG exposure in tolerant vessels, which suggests that PDE1A1 plays an important role in regulation of vascular reactivity, and also that upregulation of PDE1A1 due to chronic NTG treatment at least partially contributes to nitrate tolerance.

	Acknowledgments

 
This work was supported in part by National Institutes of Health grant HL-63462 (to Dr Berk), American Heart Association Research Grant 0030302T (to Dr Yan), and a medical school grant from Merck to Dr Berk. Dr Kim was partially supported by Yonsei University, Seoul, Korea. We thank Dr Matthew G. Melaragno and Amy M. Mohan for technical support on animal surgeries.

Received May 11, 2001; revision received August 16, 2001; accepted August 22, 2001.

	References

Top Abstract Introduction Methods Results Discussion References

 

1. Abrams J. A reappraisal of nitrate therapy. JAMA. 1988; 259: 396–401.[Abstract]
   
2. Munzel T, Kurz S, Heitzer T, et al. New insights into mechanisms underlying nitrate tolerance. Am J Cardiol. 1996; 77: 24C–30C.[Medline] [Order article via Infotrieve]
   
3. Munzel T, Heitzer T, Kurz S, et al. Dissociation of coronary vascular tolerance and neurohormonal adjustments during long-term nitroglycerin therapy in patients with stable coronary artery disease. J Am Coll Cardiol. 1996; 27: 297–303.[Abstract]
   
4. Packer M, Lee WH, Kessler PD, et al. Prevention and reversal of nitrate tolerance in patients with congestive heart failure. N Engl J Med. 1987; 317: 799–804.[Abstract]
   
5. Munzel T, Giaid A, Kurz S, et al. Evidence for a role of endothelin 1 and protein kinase C in nitroglycerin tolerance. Proc Natl Acad Sci U S A. 1995; 92: 5244–5248.[Abstract/Free Full Text]
   
6. Munzel T, Mollnau H, Hartmann M, et al. Effects of a nitrate-free interval on tolerance, vasoconstrictor sensitivity and vascular superoxide production. J Am Coll Cardiol. 2000; 36: 628–634.[Abstract/Free Full Text]
   
7. Ahn HS, Crim W, Romano M, et al. Effects of selective inhibitors on cyclic nucleotide phosphodiesterases of rabbit aorta. Biochem Pharmacol. 1989; 38: 3331–3339.[Medline] [Order article via Infotrieve]
   
8. Munzel T, Li H, Mollnau H, et al. Effects of long-term nitroglycerin treatment on endothelial nitric oxide synthase (NOS III) gene expression, NOS III–mediated superoxide production, and vascular NO bioavailability. Circ Res. 2000; 86: E7–E12.
   
9. Rybalkin SD, Bornfeldt KE, Sonnenburg WK, et al. Calmodulin-stimulated cyclic nucleotide phosphodiesterase (PDE1C) is induced in human arterial smooth muscle cells of the synthetic, proliferative phenotype. J Clin Invest. 1997; 100: 2611–2621.[Medline] [Order article via Infotrieve]
   
10. Sonnenburg WK, Rybalkin SD, Bornfeldt KE, et al. Identification, quantitation, and cellular localization of PDE1 calmodulin-stimulated cyclic nucleotide phosphodiesterases. Methods. 1998; 14: 3–19.[Medline] [Order article via Infotrieve]
    
11. De Garavilla L, Pagani ED, Buchholz RA, et al. Zaprinast, but not dipyridamole, reverses hemodynamic tolerance to nitroglycerin in vivo. Eur J Pharmacol. 1996; 313: 89–96.[Medline] [Order article via Infotrieve]
    
12. Ishida T, Ishida M, Suero J, et al. Agonist-stimulated cytoskeletal reorganization and signal transduction at focal adhesions in vascular smooth muscle cells require c-Src. J Clin Invest. 1999; 103: 789–797.[Medline] [Order article via Infotrieve]
    
13. Miller JR, Wells JN. Effects of isoproterenol on active force and Ca²⁺ X calmodulin-sensitive phosphodiesterase activity in porcine coronary artery. Biochem Pharmacol. 1987; 36: 1819–1824.[Medline] [Order article via Infotrieve]
    
14. Sonnenburg WK, Seger D, Beavo JA. Molecular cloning of a cDNA encoding the "61-kDa" calmodulin-stimulated cyclic nucleotide phosphodiesterase: tissue-specific expression of structurally related isoforms. J Biol Chem. 1993; 268: 645–652.[Abstract/Free Full Text]
    
15. Ushio-Fukai M, Yamamoto H, Toyofuku K, et al. Changes in the cytosolic Ca²⁺ concentration and Ca²⁺-sensitivity of the contractile apparatus during angiotensin II-induced desensitization in the rabbit femoral artery. Br J Pharmacol. 2000; 129: 425–436.[Medline] [Order article via Infotrieve]
    
16. Souness JE, Brazdil R, Diocee BK, et al. Role of selective cyclic GMP phosphodiesterase inhibition in the myorelaxant actions of M&B 22,948, MY-5445, vinpocetine and 1-methyl-3-isobutyl-8-(methylamino)xanthine. Br J Pharmacol. 1989; 98: 725–734.[Medline] [Order article via Infotrieve]
    
17. Munzel T, Sayegh H, Freeman BA, et al. Evidence for enhanced vascular superoxide anion production in nitrate tolerance: a novel mechanism underlying tolerance and cross-tolerance. J Clin Invest. 1995; 95: 187–194.
    
18. Molina CR, Andresen JW, Rapoport RM, et al. Effect of in vivo nitroglycerin therapy on endothelium-dependent and independent vascular relaxation and cyclic GMP accumulation in rat aorta. J Cardiovasc Pharmacol. 1987; 10: 371–378.[Medline] [Order article via Infotrieve]
    
19. Axelsson KL, Andersson RG. Tolerance towards nitroglycerin, induced in vivo, is correlated to a reduced cGMP response and an alteration in cGMP turnover. Eur J Pharmacol. 1983; 88: 71–79.[Medline] [Order article via Infotrieve]
    
20. Jaiswal RK. Endothelin inhibits the atrial natriuretic factor stimulated cGMP production by activating the protein kinase C in rat aortic smooth muscle cells. Biochem Biophys Res Commun. 1992; 182: 395–402.[Medline] [Order article via Infotrieve]
    
21. Lange RL, Reid MS, Tresch DD, et al. Nonatheromatous ischemic heart disease following withdrawal from chronic industrial nitroglycerin exposure. Circulation. 1972; 46: 666–678.[Abstract/Free Full Text]
    
22. Brien JF, McLaughlin BE, Breedon TH, et al. Biotransformation of glyceryl trinitrate occurs concurrently with relaxation of rabbit aorta. J Pharmacol Exp Ther. 1986; 237: 608–614.[Abstract/Free Full Text]
    
23. Axelsson KL, Ahlner J. Nitrate tolerance from a biochemical point of view. Drugs. 1987; 33: 63–68.
    
24. Mulsch A, Oelze M, Kloss S, et al. Effects of in vivo nitroglycerin treatment on activity and expression of the guanylyl cyclase and cGMP-dependent protein kinase and their downstream target vasodilator-stimulated phosphoprotein in aorta. Circulation. 2001; 103: 2188–2194.[Abstract/Free Full Text]
    
25. Pagani ED, VanAller GS, O’Connor B, et al. Reversal of nitroglycerin tolerance in vitro by the cGMP-phosphodiesterase inhibitor zaprinast. Eur J Pharmacol. 1993; 243: 141–147.[Medline] [Order article via Infotrieve]
    

This article has been cited by other articles:

				L. De Franceschi, O. S. Platt, G. Malpeli, A. Janin, A. Scarpa, C. Leboeuf, Y. Beuzard, E. Payen, and C. Brugnara Protective effects of phosphodiesterase-4 (PDE-4) inhibition in the early phase of pulmonary arterial hypertension in transgenic sickle cell mice FASEB J, June 1, 2008; 22(6): 1849 - 1860. [Abstract] [Full Text] [PDF]

				D. A. Kass, E. Takimoto, T. Nagayama, and H. C. Champion Phosphodiesterase regulation of nitric oxide signaling Cardiovasc Res, July 15, 2007; 75(2): 303 - 314. [Abstract] [Full Text] [PDF]

				W. J. Perkins, M. Taniguchi, D. O. Warner, E. N. Chini, and K. A. Jones Reduction in soluble guanylyl cyclase-specific activity following prolonged treatment of porcine pulmonary artery with nitric oxide Am J Physiol Lung Cell Mol Physiol, July 1, 2007; 293(1): L84 - L95. [Abstract] [Full Text] [PDF]

				G. R. Thomas, J. M. DiFabio, T. Gori, and J. D. Parker Once Daily Therapy With Isosorbide-5-Mononitrate Causes Endothelial Dysfunction in Humans: Evidence of a Free-Radical-Mediated Mechanism J. Am. Coll. Cardiol., March 27, 2007; 49(12): 1289 - 1295. [Abstract] [Full Text] [PDF]

				K. Omori and J. Kotera Overview of PDEs and Their Regulation Circ. Res., February 16, 2007; 100(3): 309 - 327. [Abstract] [Full Text] [PDF]

				A. T. Bender and J. A. Beavo Cyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical Use Pharmacol. Rev., September 1, 2006; 58(3): 488 - 520. [Abstract] [Full Text] [PDF]

				J. D. MacPherson, T. D. Gillespie, H. A. Dunkerley, D. H. Maurice, and B. M. Bennett Inhibition of Phosphodiesterase 5 Selectively Reverses Nitrate Tolerance in the Venous Circulation J. Pharmacol. Exp. Ther., April 1, 2006; 317(1): 188 - 195. [Abstract] [Full Text] [PDF]

				O. V. Evgenov, C. J. Busch, N. V. Evgenov, R. Liu, B. Petersen, G. E. Falkowski, B. Petho, A. Vas, K. D. Bloch, W. M. Zapol, et al. Inhibition of phosphodiesterase 1 augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs with acute pulmonary hypertension Am J Physiol Lung Cell Mol Physiol, April 1, 2006; 290(4): L723 - L729. [Abstract] [Full Text] [PDF]

				K. E. Bornfeldt Nuclear Signaling in Smooth Muscle Cells: Cyclic Nucleotide Phosphodiesterase 1A Moves In Circ. Res., March 31, 2006; 98(6): 720 - 722. [Full Text] [PDF]

				D. J. Nagel, T. Aizawa, K.-I. Jeon, W. Liu, A. Mohan, H. Wei, J. M. Miano, V. A. Florio, P. Gao, V. A. Korshunov, et al. Role of Nuclear Ca2+/Calmodulin-Stimulated Phosphodiesterase 1A in Vascular Smooth Muscle Cell Growth and Survival Circ. Res., March 31, 2006; 98(6): 777 - 784. [Abstract] [Full Text] [PDF]

				R. Tahseldar-Roumieh, R. Ghali-Ghoul, C. Lugnier, and R. Sabra Effect of phosphodiesterase 5 inhibitor on alteration in vascular smooth muscle sensitivity and renal function in rats with liver cirrhosis Am J Physiol Heart Circ Physiol, January 1, 2006; 290(1): H481 - H488. [Abstract] [Full Text] [PDF]

				B. Ding, J.-i. Abe, H. Wei, H. Xu, W. Che, T. Aizawa, W. Liu, C. A. Molina, J. Sadoshima, B. C. Blaxall, et al. A positive feedback loop of phosphodiesterase 3 (PDE3) and inducible cAMP early repressor (ICER) leads to cardiomyocyte apoptosis PNAS, October 11, 2005; 102(41): 14771 - 14776. [Abstract] [Full Text] [PDF]

				T. Munzel, A. Daiber, and A. Mulsch Explaining the Phenomenon of Nitrate Tolerance Circ. Res., September 30, 2005; 97(7): 618 - 628. [Abstract] [Full Text] [PDF]

				X. Pi, G. Garin, L. Xie, Q. Zheng, H. Wei, J.-i. Abe, C. Yan, and B. C. Berk BMK1/ERK5 Is a Novel Regulator of Angiogenesis by Destabilizing Hypoxia Inducible Factor 1{alpha} Circ. Res., June 10, 2005; 96(11): 1145 - 1151. [Abstract] [Full Text] [PDF]

				T. Watanabe, T. A. Barker, and B. C. Berk Angiotensin II and the Endothelium: Diverse Signals and Effects Hypertension, February 1, 2005; 45(2): 163 - 169. [Abstract] [Full Text] [PDF]

				T. Munzel, R. Feil, A. Mulsch, S. M. Lohmann, F. Hofmann, and U. Walter Physiology and Pathophysiology of Vascular Signaling Controlled by Cyclic Guanosine 3',5'-Cyclic Monophosphate-Dependent Protein Kinase Circulation, November 4, 2003; 108(18): 2172 - 2183. [Full Text] [PDF]

				V. Gerzanich, A. Ivanov, S. Ivanova, J. B. Yang, H. Zhou, Y. Dong, and J. M. Simard Alternative Splicing of cGMP-Dependent Protein Kinase I in Angiotensin-Hypertension: Novel Mechanism for Nitrate Tolerance in Vascular Smooth Muscle Circ. Res., October 31, 2003; 93(9): 805 - 812. [Abstract] [Full Text] [PDF]

				T. Aizawa, H. Wei, J. M. Miano, J.-i. Abe, B. C. Berk, and C. Yan Role of Phosphodiesterase 3 in NO/cGMP-Mediated Antiinflammatory Effects in Vascular Smooth Muscle Cells Circ. Res., September 5, 2003; 93(5): 406 - 413. [Abstract] [Full Text] [PDF]

				D. H. Maurice, D. Palmer, D. G. Tilley, H. A. Dunkerley, S. J. Netherton, D. R. Raymond, H. S. Elbatarny, and S. L. Jimmo Cyclic Nucleotide Phosphodiesterase Activity, Expression, and Targeting in Cells of the Cardiovascular System Mol. Pharmacol., September 1, 2003; 64(3): 533 - 546. [Abstract] [Full Text] [PDF]

				S. D. Rybalkin, C. Yan, K. E. Bornfeldt, and J. A. Beavo Cyclic GMP Phosphodiesterases and Regulation of Smooth Muscle Function Circ. Res., August 22, 2003; 93(4): 280 - 291. [Abstract] [Full Text] [PDF]

				S. Muller, U. Laber, J. Mullenheim, W. Meyer, and G. Kojda Preserved endothelial function after long-term eccentric isosorbide mononitrate despite moderate nitrate tolerance J. Am. Coll. Cardiol., June 4, 2003; 41(11): 1994 - 2000. [Abstract] [Full Text] [PDF]

				C. Yan, D. Kim, T. Aizawa, and B. C. Berk Functional Interplay Between Angiotensin II and Nitric Oxide: Cyclic GMP as a Key Mediator Arterioscler. Thromb. Vasc. Biol., January 1, 2003; 23(1): 26 - 36. [Abstract] [Full Text] [PDF]

				T. Gori and J. D. Parker Nitrate Tolerance: A Unifying Hypothesis Circulation, November 5, 2002; 106(19): 2510 - 2513. [Full Text] [PDF]

				J. D. Parker and T. Gori Tolerance to the Organic Nitrates: New Ideas, New Mechanisms, Continued Mystery Circulation, November 6, 2001; 104(19): 2263 - 2265. [Full Text] [PDF]

				M. D. Frame, R. J. Fox, D. Kim, A. Mohan, B. C. Berk, and C. Yan Diminished arteriolar responses in nitrate tolerance involve ROS and angiotensin II Am J Physiol Heart Circ Physiol, June 1, 2002; 282(6): H2377 - H2385. [Abstract] [Full Text] [PDF]